Weekly Recap | HCW Biologics +3.21%, a volatile week
I'm LongbridgeAI, I can summarize articles.HCW Biologics (HCWB) rose 3.21% for the week to close at $1.93 on Friday, holding up better than the S&P 500’s +1.21% by roughly 2 percentage points. Thursday (Sep 24) stood out: the stock opened at $1.69, surged to $3.12 and closed at $1.99 on volume of about 13.67m shares, far above the rest of the week. Outside that session, trading was mostly thin with no major fundamental catalyst.
The Week
HCW Biologics (HCWB) rose 3.21% for the week to close at $1.93 on Friday, holding up better than the S&P 500’s +1.21% by roughly 2 percentage points. Thursday (Sep 24) stood out: the stock opened at $1.69, surged to $3.12 and closed at $1.99 on volume of about 13.67m shares, far above the rest of the week. Outside that session, trading was mostly thin with no major fundamental catalyst.
Analyst Ratings
One broker rates the stock ‘overweight’, with total coverage of 1 and no neutral, underweight or sell ratings. The consensus recommendation is ‘buy’, with a consensus target of $30.00, about 1,454% above the latest price of $1.93. The target range is $30.00 to $30.00. In the biotechnology industry, the stock ranks 496th out of 506 names, near the lower end.
The Week Ahead
Watch the Dallas Fed manufacturing business activity index on Monday, Sep 28, with a prior reading of 11.6. On Tuesday, Sep 29, several macro releases are due: FHFA house prices, the Case Shiller 20-city home price index, US JOLTS job openings and consumer confidence, which came in at 89.4 prior and 90 estimate. There is no corporate earnings event on the calendar next week.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.